---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000107"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:43:57.678882+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025

## Summary
- Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).
- Cash and equivalents $635M as of March 31, 2024; R&D expenses $66.1M in Q4.
- Following FDA Type B meeting, on track to initiate 4-5 registrational studies for IMVT-1402 by March 31, 2025.
- Batoclimab MG topline results expected by end of fiscal 2025; CIDP trial extended ~2 quarters before unblinding.
- Composition-of-matter patent for IMVT-1402 issued with term through June 2043.

## SEC filing metadata
- accession: 0001764013-24-000107
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/0001764013-24-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/imvt-20240529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000107
- JSON: https://secwatch.observer/filing/0001764013-24-000107.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.